Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295100 · ClinicalTrials.gov registry record · Phase 2
Tamoxifen-MRI Study
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00295100: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00295100 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00295100, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial. Study participants will be randomly assigned to receive either tamoxifen or placebo for one year. Participants will subsequently be followed for one year off of medication. The primary objective is to evaluate the effectiveness of tamoxifen in reducing breast density by mammogram.
Interventions
- DRUG Tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2000-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295100
The ClinicalTrials.gov registry entry for NCT00295100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tamoxifen is the first listed.
NCT00295100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295100 about?
NCT00295100 is a clinical study titled "Tamoxifen-MRI Study". The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial. Study participants will be randomly assigned to receive either tamoxifen or placebo for one year. Participants will subsequently be followed for one year off of medication. The primary objective is to evalu...
What is the current status of trial NCT00295100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2000-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00295100?
The interventions under investigation include: Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT00295100?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.